| A Study of SGN-B6A in Chinese Participants With Advanced Solid Tumors (NCT06549816) | Seagen, a wholly owned subsidiary of Pfizer | 2024-08-21 |
| A Study of SGN-MesoC2 in Advanced Solid Tumors (NCT06466187) | Seagen, a wholly owned subsidiary of Pfizer | 2024-08-02 |
| A Safety Study of PF-08046044/SGN-35C in Adults With Advanced Cancers (NCT06254495) | Seagen, a wholly owned subsidiary of Pfizer | 2024-05-28 |
| A Study of Disitamab Vedotin With Other Anticancer Drugs in Solid Tumors (NCT06157892) | Seagen, a wholly owned subsidiary of Pfizer | 2024-05-20 |
| A Safety Study of PF-08046045/SGN-35T in Adults With Advanced Cancers (NCT06120504) | Seagen, a wholly owned subsidiary of Pfizer | 2024-02-29 |
| A Study of SGN-B6A Versus Docetaxel in Previously Treated Non-small Cell Lung Cancer (NCT06012435) | Seagen, a wholly owned subsidiary of Pfizer | 2024-02-21 |
| A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors (NCT06131840) | Seagen, a wholly owned subsidiary of Pfizer | 2023-11-20 |
| A Study of Disitamab Vedotin in Previously Treated Solid Tumors That Express HER2 (NCT06003231) | Seagen, a wholly owned subsidiary of Pfizer | 2023-11-14 |
| A Study of PF-08046052/SGN-EGFRd2 in Advanced Solid Tumors (NCT05983133) | Seagen, a wholly owned subsidiary of Pfizer | 2023-11-14 |
| HER2 and LA/mUC: A Multi-country Chart Review Cohort Study (NCT05902494) | Seagen, a wholly owned subsidiary of Pfizer | 2023-06-29 |
| A Study of PF-08046049/SGN-BB228 in Advanced Melanoma and Other Solid Tumors (NCT05571839) | Seagen, a wholly owned subsidiary of Pfizer | 2023-01-03 |
| A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors (NCT05208762) | Seagen, a wholly owned subsidiary of Pfizer | 2022-10-25 |
| A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer (NCT05253651) | Seagen, a wholly owned subsidiary of Pfizer | 2022-10-24 |
| A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2 (NCT04879329) | Seagen, a wholly owned subsidiary of Pfizer | 2022-05-03 |
| A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer (NCT05132582) | Seagen, a wholly owned subsidiary of Pfizer | 2022-03-07 |
| A Study of Felmetatug Vedotin/SGN-B7H4V in Advanced Solid Tumors (NCT05194072) | Seagen, a wholly owned subsidiary of Pfizer | 2022-01-12 |
| Brentuximab Vedotin With Pembrolizumab in Metastatic Solid Tumors (NCT04609566) | Seagen, a wholly owned subsidiary of Pfizer | 2021-01-26 |
| Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 Alterations (NCT04579380) | Seagen, a wholly owned subsidiary of Pfizer | 2021-01-11 |
| A Study of Tucatinib Plus Trastuzumab Deruxtecan in HER2+ Breast Cancer (NCT04539938) | Seagen, a wholly owned subsidiary of Pfizer | 2020-12-01 |
| A Study of Brentuximab Vedotin and CHP in Frontline Treatment of PTCL With Less Than 10% CD30 Expression (NCT04569032) | Seagen, a wholly owned subsidiary of Pfizer | 2020-11-12 |
| Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal Cancers (NCT04430738) | Seagen, a wholly owned subsidiary of Pfizer | 2020-09-15 |
| Brentuximab Vedotin Plus Lenalidomide and Rituximab for the Treatment of Relapsed/Refractory DLBCL (NCT04404283) | Seagen, a wholly owned subsidiary of Pfizer | 2020-08-20 |
| A Safety Study of SEA-CD70 in Patients With Myeloid Malignancies (NCT04227847) | Seagen, a wholly owned subsidiary of Pfizer | 2020-08-07 |
| A Study of Sigvotatug Vedotin in Advanced Solid Tumors (NCT04389632) | Seagen, a wholly owned subsidiary of Pfizer | 2020-06-08 |
| A Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer (NCT03975647) | Seagen, a wholly owned subsidiary of Pfizer | 2019-10-02 |
| Safety and Efficacy of Tisotumab Vedotin Monotherapy & in Combination With Other Cancer Agents in Subjects With Cervical Cancer (NCT03786081) | Seagen, a wholly owned subsidiary of Pfizer | 2019-02-27 |
| Efficacy and Safety Study of Tisotumab Vedotin for Patients With Solid Tumors (NCT03485209) | Seagen, a wholly owned subsidiary of Pfizer | 2018-06-25 |